|
Phase I, open-label study of MEDI0680, an anti-programmed cell death-1 (PD-1) antibody, in combination with MEDI4736, an anti-programmed cell death ligand-1 (PD-L1) antibody, in patients with advanced malignancies. |
|
|
Research Funding - MedImmune (Inst) |
|
|
Honoraria - Astellas Pharma |
Consulting or Advisory Role - Bristol-Myers Squibb; Merck; Novartis |
Research Funding - AstraZeneca/MedImmune (Inst); Bristol-Myers Squibb (Inst); Genentech (Inst); GlaxoSmithKline (Inst); Lilly/ImClone (Inst); Merck (Inst); Novartis (Inst); Pfizer (Inst); VentiRx (Inst) |
Travel, Accommodations, Expenses - Merck; Novartis |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
|
Stock and Other Ownership Interests - MedImmune |
Travel, Accommodations, Expenses - MedImmune |
|
|
Employment - Suburban Hosptial |
Patents, Royalties, Other Intellectual Property - MedImmune |
Other Relationship - MedImmune |
|
|
Research Funding - MedImmune (Inst) |